February 21, 2020

The Honorable Richard C. Shelby  
Chairman  
Subcommittee on Defense  
Committee on Appropriations  
United States Senate  
Washington, DC  20510

The Honorable Richard J. Durbin  
Ranking Member  
Subcommittee on Defense  
Committee on Appropriations  
United States Senate  
Washington, DC  20510

SUBJECT: Including Peripheral Neuropathy in the Peer-Reviewed Medical Research Program

Dear Chairman Shelby and Ranking Member Durbin,

Vietnam Veterans of America and Veterans for Common Sense support the inclusion of “peripheral neuropathy” among the disorders and conditions eligible for research funding in the Fiscal Year (FY) 2021 Defense Appropriations Act under the Peer-Reviewed Medical Research Program (PRMRP) within the Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP).

Affecting an estimated 30 million Americans, peripheral neuropathy refers to the many conditions that involve damage to the peripheral nervous system. The disabling symptoms of peripheral neuropathy typically include pain (sometimes severe), prickling, and/or numbness in the hands and feet that may spread to the arms and legs. Symptoms may also include extreme sensitivity to touch; sleep difficulties; significant mobility problems; poor balance and falls; tremors; heat intolerance and altered sweating; muscle wasting, weakness, and paralysis; and bowel, bladder, or digestive problems.

Peripheral neuropathy is common among the veterans community, particularly those diagnosed with diabetes, hepatitis C, and HIV. Cancer patients who have undergone chemotherapy treatment commonly develop peripheral neuropathy. The Gulf War Illness Research Program (GWIRP) within the CDMRP has supported some promising research studies on the correlation between Gulf War Illness and Small Fiber Peripheral Neuropathy (SFPN) – one of more than 100 types of peripheral neuropathy, each with its own symptoms and disease course. The U.S. Department of Veterans Affairs (VA), under specific conditions, presumes veterans’ early-onset peripheral neuropathy is related to their exposure to Agent Orange or other herbicides during service.
The mission of the PRMRP is to “improve the health, care, and well-being of all Military Service members, Veterans, and beneficiaries.” Broad peripheral neuropathy research across the full spectrum of military and veteran populations will enhance rather than duplicate existing federal government research efforts, bringing us closer to finding a cure for the estimated 30 million Americans coping with these debilitating conditions – including the untold numbers of Vietnam, Gulf War, and other veterans and current and future military service members.

We therefore urge you to again include the designation of “peripheral neuropathy” among the disorders eligible for research funded by the PRMRP in the FY 2021 Defense Appropriations Act. Thank you for your consideration of this request.

John Rowan
National President/CEO
Vietnam Veterans of America

Anthony Hardie
National Chair and Director
Veterans for Common Sense